The HIV field is in a critical period to develop rapidly and evaluate immunogens that build upon findings from the RV144 regimen and to put forth rational new paradigms for protection. Over the past seven years, the HVTN Laboratory Program was a major leader and substantial contributor to understanding vaccine effects and immune correlates in the VaxGen, Step and RV144 efficacy trials. We raised the standards of immune monitoring in clinical trials, consistently providing high quality data in a GCLP setting using validated or standardized assays. When indicated, we rapidly shifted priorities, broadened collaborations and improved assays. Our Laboratory Center proposes to continue the performance of high quality, state-of-the-art laboratory research, which will accelerate the development of a safe and efficacious HIV vaccine. To accomplish this, we will execute protocol-related, validated endpoint laboratory assays and more comprehensive immunologic investigations to provide unambiguous measurements of vaccine immunogenicity (Aim 1). We will improve existing and adopt novel technologies that can enhance our knowledge of ways vaccines prime the immune system (Aim 2). In phase 2b-3 trials, we will determine vaccine efficacy and investigate potential immune correlates and mechanisms of protection through vaccination (Aim 3). We will optimize strategies to assess vaccine-induced mucosal defense against HIV-1 invasion (Aim 4). Combination strategies with vaccines to prevent HIV will be an important direction for the HVTN, and we will investigate how these may alter and improve immune responses (Aim 5). Finally, we will apply our expertise to fill gaps in development of vaccines for other major global health concerns (Aim 6). Headquartered at FHCRC, the Laboratory Center will integrate its activities seamlessly with the HVTN Leadership and Operations Center and the Statistical and Data Management Center, and cooperatively with the DAIDS Vaccine Clinical Branch. Our core laboratories will continue to be based at FHCRC and Duke University, and we will expand laboratory capacity in South Africa as needed to support efficacy studies.

Public Health Relevance

A safe and effective HIV vaccine is needed to halt the HIV epidemic. We will conduct high quality laboratory studies in support of HVTN HIV vaccine trials that can inform the field about what a candidate HIV vaccine can and cannot do in the populations who would benefit most. Our efforts will provide a rich database that will help advance vaccine development for HIV and other globally important pathogens.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-EB-A (S1))
Program Officer
D'Souza, Patricia D
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Fred Hutchinson Cancer Research Center
United States
Zip Code
Stekler, Joanne D; Ure, George; O'Neal, Joshua D et al. (2016) Performance of Determine Combo and other point-of-care HIV tests among Seattle MSM. J Clin Virol 76:8-13
Hughes, Sean M; Shu, Zhiquan; Levy, Claire N et al. (2016) Cryopreservation of Human Mucosal Leukocytes. PLoS One 11:e0156293
Fong, Youyi; Yin, Shuxin; Huang, Ying (2016) Combining biomarkers linearly and nonlinearly for classification using the area under the ROC curve. Stat Med 35:3792-809
Lama, Javier R; Karuna, Shelly T; Grant, Shannon P et al. (2016) Transient Peripheral Immune Activation follows Elective Sigmoidoscopy or Circumcision in a Cohort Study of MSM at Risk of HIV Infection. PLoS One 11:e0160487
Gray, Glenda E; Mayer, Kenneth H; Elizaga, Marnie L et al. (2016) Subtype C gp140 Vaccine Boosts Immune Responses Primed by the South African AIDS Vaccine Initiative DNA-C2 and MVA-C HIV Vaccines after More than a 2-Year Gap. Clin Vaccine Immunol 23:496-506
Lhomme, Edouard; Richert, Laura; Moodie, Zoe et al. (2016) Early CD4+ T Cell Responses Are Associated with Subsequent CD8+ T Cell Responses to an rAd5-Based Prophylactic Prime-Boost HIV Vaccine Strategy. PLoS One 11:e0152952
Churchyard, Gavin; Mlisana, Koleka; Karuna, Shelly et al. (2016) Sequential Immunization with gp140 Boosts Immune Responses Primed by Modified Vaccinia Ankara or DNA in HIV-Uninfected South African Participants. PLoS One 11:e0161753
Hertz, T; Logan, M G; Rolland, M et al. (2016) A study of vaccine-induced immune pressure on breakthrough infections in the Phambili phase 2b HIV-1 vaccine efficacy trial. Vaccine 34:5792-5801
Mkhize, Nonhlanhla N; Durgiah, Raveshni; Ashley, Vicki et al. (2016) Broadly neutralizing antibody specificities detected in the genital tract of HIV-1 infected women. AIDS 30:1005-14
Lemos, M P; Karuna, S T; Mize, G J et al. (2016) In men at risk of HIV infection, IgM, IgG1, IgG3, and IgA reach the human foreskin epidermis. Mucosal Immunol 9:798-808

Showing the most recent 10 out of 107 publications